Lupin’s Goa manufacturing plant gets EIR from US FDA

Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (FDA) for its Goa manufacturing facility, after the inspection of the facility in September 2021. The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

Commenting on the development, Nilesh Gupta, Managing Director, Lupin, said, “This is a positive development………. The Goa site has an important place in the US market with the number of affordable, quality medicines we supply, and we now look forward to new products flowing out of the site again.”